{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:37:13Z","timestamp":1783420633437,"version":"3.54.6"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To quantitatively evaluate intratumoral habitats on dynamic contrast-enhanced (DCE) breast MRI to predict pathologic breast cancer response to stereotactic ablative body radiotherapy (SABR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants underwent SABR treatment (28.5 Gy x3), baseline and post-SABR MRI, and breast-conserving surgery for ER\/PR+\u2005HER2\u2212 breast cancer. MRI analysis was performed on DCE T1-weighted images. MRI voxels were assigned eight habitats based on high (H) or low (L) maximum enhancement and the sequentially numbered dynamic sequence of maximum enhancement (H1\u22124, L1\u22124). MRI response was analyzed by percent tumor volume remaining (%VR = volume post-SABR\/volume pre-SABR), and percent habitat makeup (%HM of habitat X = habitat X voxels\/total voxels in the segmented volume). These were correlated with percent tumor bed cellularity (%TC) for pathologic response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixteen patients completed the trial. The %TC ranged 20%\u201380%. MRI %VR demonstrated strong correlations with %TC (Pearson R\u2005=\u20050.7\u20130.89). Pre-SABR tumor %HMs differed significantly from whole breasts (P\u2005=\u20050.005 to &amp;lt;0.00001). Post-SABR %HM of tumor habitat H4 demonstrated the largest change, increasing 13% (P\u2005=\u20050.039). Conversely, combined %HM for H1\u22123 decreased 17% (P\u2005=\u20050.006). This change correlated with %TC (P\u2005&amp;lt;\u20050.00001) and distinguished pathologic partial responders (\u226470 %TC) from nonresponders with 94% accuracy, 93% sensitivity, 100% specificity, 100% positive predictive value, and 67% negative predictive value.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients undergoing preoperative SABR treatment for ER\/PR+\u2005HER2\u2212 breast cancer, quantitative MRI habitat analysis of %VR and %HM change correlates with pathologic response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jbi\/wbac013","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T18:42:30Z","timestamp":1649356950000},"page":"273-284","source":"Crossref","is-referenced-by-count":10,"title":["Quantitative Changes in Intratumoral Habitats on MRI Correlate With Pathologic Response in Early-stage ER\/PR+ HER2\u2212 Breast Cancer Treated With Preoperative Stereotactic Ablative Body Radiotherapy"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-8744","authenticated-orcid":false,"given":"R","family":"Jared Weinfurtner","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdalah","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Quantitative Imaging Core , Tampa, Fl , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olya","family":"Stringfield","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Quantitative Imaging Core , Tampa, Fl , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Ataya","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaise","family":"Mooney","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilin","family":"Rosa","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Pathology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C","family":"Lee","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Surgery, Tampa , FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Khakpour","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Surgery, Tampa , FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Laronga","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Czerniecki","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Surgery, Tampa , FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Diaz","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiation Oncology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiation Oncology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Washington","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiation Oncology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kujtim","family":"Latifi","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiation Oncology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany L","family":"Niell","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Montejo","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Radiation Oncology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-7687","authenticated-orcid":false,"given":"Natarajan","family":"Raghunand","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Department of Cancer Physiology , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"issue":"3","key":"2022060715294894400_CIT0001","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1148\/rg.2021200134","article-title":"Breast MRI for evaluation of response to neoadjuvant therapy","volume":"41","author":"Reig","year":"2021","journal-title":"Radiographics"},{"issue":"5","key":"2022060715294894400_CIT0002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jnci\/djs528","article-title":"Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy","volume":"105","author":"Marinovich","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2022060715294894400_CIT0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2018.09.012","article-title":"Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapy","volume":"132","author":"Taourel","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2022060715294894400_CIT0004","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"2022060715294894400_CIT0005","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1148\/radiol.2017170180","article-title":"Imaging neoadjuvant therapy response in breast cancer","volume":"285","author":"Fowler","year":"2017","journal-title":"Radiology"},{"key":"2022060715294894400_CIT0006","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s40064-016-1800-x","article-title":"Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype","volume":"5","author":"Fukuda","year":"2016","journal-title":"Springerplus"},{"issue":"6","key":"2022060715294894400_CIT0007","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.2010.31.1258","article-title":"Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype","volume":"29","author":"Loo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022060715294894400_CIT0008","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ijrobp.2012.10.034","article-title":"Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer","volume":"85","author":"Bondiau","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022060715294894400_CIT0009","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fonc.2016.00129","article-title":"Stereotactic accelerated partial breast irradiation for early-stage breast cancer: rationale, feasibility, and early experience using the cyberknife radiosurgery delivery platform","volume":"6","author":"Obayomi-Davies","year":"2016","journal-title":"Front Oncol"},{"key":"2022060715294894400_CIT0010","doi-asserted-by":"crossref","first-page":"2734820","DOI":"10.1155\/2018\/2734820","article-title":"Establishing the role of stereotactic ablative body radiotherapy in early-stage breast cancer","volume":"2018","author":"Barry","year":"2018","journal-title":"Int J Breast Cancer"},{"key":"2022060715294894400_CIT0011","article-title":"ACR BI-RADS\u00ae Magnetic Resonance Imaging.","volume-title":"ACR BI-RADS\u00ae Atlas, Breast Imaging Reporting and Data System","author":"Morris","year":"2013"},{"issue":"2","key":"2022060715294894400_CIT0012","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1016\/j.clbc.2021.06.016","article-title":"MRI response to pre-operative stereotactic ablative body radiotherapy (SABR) in early stage ER\/PR+ HER2- breast cancer correlates with surgical pathology tumor bed cellularity","volume":"22","author":"Weinfurtner","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"2022060715294894400_CIT0013","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1148\/radiol.2018172462","article-title":"Intratumoral spatial heterogeneity at perfusion MR imaging predicts recurrence-free survival in locally advanced breast cancer treated with neoadjuvant chemotherapy","volume":"288","author":"Wu","year":"2018","journal-title":"Radiology"},{"issue":"5","key":"2022060715294894400_CIT0014","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jmri.25279","article-title":"Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy","volume":"44","author":"Wu","year":"2016","journal-title":"J Magn Reson Imaging"},{"issue":"5","key":"2022060715294894400_CIT0015","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/jmri.24921","article-title":"Heterogeneity in intratumoral regions with rapid gadolinium washout correlates with estrogen receptor status and nodal metastasis","volume":"42","author":"Chaudhury","year":"2015","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"2022060715294894400_CIT0016","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18383\/j.tom.2018.00052","article-title":"Multiparameter MRI predictors of long-term survival in glioblastoma multiforme","volume":"5","author":"Stringfield","year":"2019","journal-title":"Tomography"},{"issue":"2","key":"2022060715294894400_CIT0017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prro.2016.09.007","article-title":"Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement","volume":"7","author":"Correa","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2022060715294894400_CIT0018","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/annonc\/mdx647","article-title":"A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade","volume":"29","author":"Nuciforo","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"2022060715294894400_CIT0019","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","article-title":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group","volume":"28","author":"Provenzano","year":"2015","journal-title":"Mod Pathol"},{"issue":"2","key":"2022060715294894400_CIT0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"2022060715294894400_CIT0021","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2214\/AJR.20.23804","article-title":"Quantitative measures of background parenchymal enhancement predict breast cancer risk","volume":"217","author":"Niell","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"2022060715294894400_CIT0022","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","article-title":"A threshold selection method from gray-level histograms","volume":"9","author":"Otsu","year":"1979","journal-title":"IEEE Trans Systems Man Cybernetics"},{"key":"2022060715294894400_CIT0023","author":"Stangroom","year":"2021"},{"issue":"3","key":"2022060715294894400_CIT0024","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1148\/radiol.2018180273","article-title":"Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial","volume":"289","author":"Partridge","year":"2018","journal-title":"Radiology"},{"key":"2022060715294894400_CIT0025","doi-asserted-by":"crossref","first-page":"108701","DOI":"10.1016\/j.ejrad.2019.108701","article-title":"Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy","volume":"120","author":"Negrao","year":"2019","journal-title":"Eur J Radiol"},{"issue":"1","key":"2022060715294894400_CIT0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13058-018-1091-y","article-title":"Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)","volume":"21","author":"Gampenrieder","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2022060715294894400_CIT0027","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.clbc.2017.08.003","article-title":"Evaluation of the tumor response after neoadjuvant chemotherapy in breast cancer patients: correlation between dynamic contrast-enhanced magnetic resonance imaging and pathologic tumor cellularity","volume":"18","author":"Choi","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"2022060715294894400_CIT0028","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clbc.2018.05.009","article-title":"Magnetic resonance imaging (MRI) assessment of residual breast cancer after neoadjuvant chemotherapy: relevance to tumor subtypes and MRI interpretation threshold","volume":"18","author":"Kim","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"2022060715294894400_CIT0029","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-017-4303-8","article-title":"Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657)","volume":"165","author":"Campbell","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"2022060715294894400_CIT0030","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1245\/s10434-019-07741-w","article-title":"Validation of residual cancer burden as prognostic factor for breast cancer patients after neoadjuvant therapy","volume":"26","author":"Muller","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2022060715294894400_CIT0031","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jmri.24351","article-title":"Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy","volume":"40","author":"Jafri","year":"2014","journal-title":"J Magn Reson Imaging"},{"key":"2022060715294894400_CIT0032","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3389\/fimmu.2018.03107","article-title":"Combining radiotherapy with anti-angiogenic therapy and immunotherapy: a therapeutic triad for cancer?","volume":"9","author":"Goedegebuure","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2022060715294894400_CIT0033","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijrobp.2015.05.016","article-title":"Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery","volume":"93","author":"Song","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2022060715294894400_CIT0034","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdu118","article-title":"Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994\/BIG 1-00 phase III trial","volume":"25","author":"Bonnefoi","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Journal of Breast Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbi\/article-pdf\/4\/3\/273\/43972603\/wbac013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbi\/article-pdf\/4\/3\/273\/43972603\/wbac013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T15:30:47Z","timestamp":1654615847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbi\/article\/4\/3\/273\/6564858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,7]]},"published-print":{"date-parts":[[2022,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jbi\/wbac013","relation":{},"ISSN":["2631-6110","2631-6129"],"issn-type":[{"value":"2631-6110","type":"print"},{"value":"2631-6129","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,4,7]]}}}